Press Release
New Medical Implant Technology for Macular Degeneration in Connecticut
New Medical Implant Technology for Macular Degeneration in Connecticut
Cheshire, Conn., January 22, 2013 – For patients who have been
told there is no medical treatment for their advanced macular degeneration,
there is new hope for improving the quality of life. Dr. Randolph Kinkade, a
low vision optometrist with offices in
Cheshire, Danbury, Farmington, Litchfield, Manchester, Norwalk and Waterford,
is part of the first provider team in Connecticut offering the newly FDA
approved Implantable Miniature Telescope (IMT). The IMT is a
micro-telescope implanted into the eye of patients suffering from end-stage
age-related macular degeneration, the most advanced form of AMD and the leading
cause of blindness in older Americans. More than 15 million Americans are
affected by some form of AMD. The number of Americans afflicted with macular
degeneration is expected to double with the rapid aging of the U.S. population.
“I have been fitting Spectacle Miniature Telescopes
for twenty years for patients with macular degeneration. Now we have the ability to offer potentially
better rehabilitation options we only dreamed about a few years ago. This “bionic” technology will improve vision for
some of my patients and help them achieve a greater quality of life. I am pleased and thrilled to be part of the
first provider team in Connecticut”, says Dr. Kinkade.
Patients with end-stage AMD have a central blind
spot. This vision loss makes it difficult or impossible to see faces, read, and
perform everyday activities such as watching TV, preparing meals, and
self-care. The telescope implant has been demonstrated in clinical trials to
improve quality of life by improving patients’ vision so they can see the
things that are important to them, increase their independence, and re-engage
in everyday activities. It also may help
patients in social settings as it may allow them to recognize faces and see the
facial expressions of family and friends.
Smaller than a pea, the telescope implant uses
micro-optical technology to magnify images which would normally be seen in
one’s “straight ahead” or central, vision. The images are projected onto the
healthy portion of the retina not affected by the disease, making it possible
for patients to see more detail that may have been impossible or difficult
without the implant.
The FDA approved implant is the only
medical/surgical option that improves visual acuity by reducing the impact of
the central vision blind spot caused by end-stage AMD. However, the telescope implant is not a cure
for end-stage AMD. As with any medical intervention, potential risks and complications
exist with the telescope implant. Possible side effects include decreased
vision or vision impairing corneal swelling.
CentraSight, has developed a patient information booklet that highlights
the risks and benefits associated with the telescope implant and can be found
at www.CentraSight.com.
Dr. Kinkade's Educational IMT Video
As with any medical intervention, potential risks and
complications exist with the telescope implant. Possible side effects include
decreased vision or vision impairing corneal swelling. For AMD patients who are not ideal surgical
candidates, Dr. Kinkade can discuss and recommend other options, including
Spectacle Miniature Telescopes (SMTs).
Patients
and physicians can find more information and can watch a video about the
telescopic implant and related treatment program at www.lowvisioneyeglasses.com
or by calling (800) 756 -0766.
######
Dr. Kinkade holding an IMT |
Dr. Randolph Kinkade is a founding
member of the International Academy of Low Vision Specialists. He has a Master of Public Health degree and
is the founder of Low Vision Consulting. He is co-founder of See and Hear America, a
company designed to help those with vision and or hearing loss.
Dr. Kinkade has been treating the
rehabilitation needs of patients with AMD and other vision limiting conditions
for over 30 years. He continues to study the causes and treatment of macular
degeneration from a medical and public health point of view.
He is a member of the Vision
Rehabilitation Section of the American Optometric Association and the Low
Vision Section of the American Academy of Optometry. For more information visit
http://www.lowvisioneyeglasses.com.
(800) 756-0766
rkinkade@optonline.net
rkinkade@optonline.net
Cheshire - Danbury - Farmington - Litchfield - Manchester - Norwalk - Waterford
About
CentraSight
CentraSight
is the first-ever telescope implant for end-stage age-related macular
degeneration (AMD), the most advanced form of AMD and the leading cause of
blindness in older Americans. Patients
with end-stage AMD have a central blind spot or missing area in their vision
that makes it difficult or impossible to see faces, read, and perform everyday
activities. The CentraSight Treatment Program allows patients to see details
again by implanting a tiny telescope in the eye in an outpatient procedure,
then coordinating with vision specialists to help the patient learn how to use
their new vision for everyday activities. For more information visit www.CentraSight.com.
-----#-----
No comments:
Post a Comment